Holen Sie sich die Stockscreener-App
13.49
5.86%
-0.84
Handel nachbörslich:
13.40
-0.09
-0.67%
Schlusskurs vom Vortag:
$14.33
Offen:
$14.35
24-Stunden-Volumen:
1.18M
Relative Volume:
0.69
Marktkapitalisierung:
$1.51B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-9.6357
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
-7.98%
1M Leistung:
+10.48%
6M Leistung:
-16.11%
1J Leistung:
-9.28%
1-Tages-Spanne:
$13.24
$14.45
1-Wochen-Bereich:
$13.24
$14.77
52-Wochen-Spanne:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.49 | 1.60B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
132.57 | 232.02B | 43.11B | 13.94B | 6.78B | 7.9963 |
|
BSX
Boston Scientific Corp
|
95.41 | 144.14B | 18.49B | 2.50B | 3.49B | 1.6801 |
|
SYK
Stryker Corp
|
364.60 | 141.53B | 23.82B | 2.92B | 4.02B | 7.5574 |
|
MDT
Medtronic Plc
|
95.45 | 123.78B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
73.94 | 44.14B | 5.69B | 1.41B | 577.90M | 6.9828 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
NovoCure (NVCR): Evaluating Valuation as METIS Phase 3 Brain Metastases Results Reach Industry Conference Milestone - simplywall.st
Using data tools to time your NovoCure Limited exitJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
NovoCure's (NVCR) Sell (E+) Rating Reiterated at Weiss Ratings - MarketBeat
Final METIS Trial Results for TTFields Therapy Could Be a Game Changer for NovoCure (NVCR) - simplywall.st
Should I buy NovoCure Limited (038) stock before earnings seasonJuly 2025 Short Interest & Accurate Buy Signal Alerts - newser.com
Why NovoCure Limited (038) stock remains top ratedEarnings Summary Report & Free Weekly Chart Analysis and Trade Guides - newser.com
NovoCure Ltd. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
NovoCure (NASDAQ:NVCR) vs. Evogene (NASDAQ:EVGN) Head-To-Head Analysis - Defense World
NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of “Hold” by Analysts - Defense World
Published on: 2025-10-05 04:02:03 - newser.com
Analyzing NovoCure Limited with multi timeframe chartsQuarterly Trade Report & Low Volatility Stock Recommendations - newser.com
NovoCure (NVCR): Assessing Valuation After Positive Phase 3 METIS Trial Results Unveiled - simplywall.st
Volume spikes in NovoCure Limited stock – what they mean2025 Support & Resistance & Capital Protection Trading Alerts - newser.com
Will NovoCure Limited (038) stock keep high P E multiplesRecession Risk & Safe Entry Trade Signal Reports - newser.com
Why NovoCure (NVCR) Is Up 9.9% After Phase 3 METIS Trial Success in Brain Metastases - simplywall.st
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Outlook & Short-Term High Return Strategies - newser.com
Medical Technology Firm Novocure Schedules Q3 2025 Financial Results with Investor Conference Call - Stock Titan
Novocure to Report Third Quarter 2025 Financial Results - The Globe and Mail
Why NovoCure Limited is moving todayQuarterly Earnings Report & Low Risk High Reward Trade Ideas - newser.com
NovoCure stock rating reiterated at Buy by H.C. Wainwright on METIS trial data - Investing.com Nigeria
NovoCure's (NVCR) "Neutral" Rating Reaffirmed at Wedbush - MarketBeat
Pattern recognition hints at NovoCure Limited upsideTrade Volume Report & Real-Time Chart Breakout Alerts - newser.com
Novocure (NVCR) Announces Positive Phase 3 METIS Trial Results - GuruFocus
Novocure’s cancer therapy delays brain metastases progression By Investing.com - Investing.com Australia
Novocure’s cancer therapy delays brain metastases progression - Investing.com India
15-Month Brain Metastases Control: Novocure's TTFields Therapy Shows Breakthrough in Lung Cancer Trial - Stock Titan
Live market analysis of NovoCure LimitedJuly 2025 Selloffs & Safe Entry Point Identification - newser.com
Why NovoCure Limited stock is rated strong buyJuly 2025 Trends & Precise Swing Trade Entry Alerts - newser.com
Washington Capital Management Inc. Invests $374,000 in NovoCure Limited $NVCR - MarketBeat
Novocure to Present Final Results from the Pivotal Phase 3 METIS Trial of its Tumor Treating Fields (TTFields) Therapy for Brain Metastases from Non-Small Cell Lung Cancer at 2025 ASTRO Annual Meeting - Ariva
How NovoCure Limited stock benefits from strong dollarJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Regression analysis insights on NovoCure Limited performancePortfolio Risk Report & Fast Gain Swing Alerts - newser.com
Published on: 2025-09-28 23:33:37 - newser.com
NovoCure Limited stock outlook for YEARJuly 2025 Intraday Action & Fast Gain Stock Tips - newser.com
Is NovoCure Limited (038) stock a buy on weaknessJuly 2025 Action & Technical Pattern Based Buy Signals - newser.com
42,600 Shares in NovoCure Limited $NVCR Purchased by Strs Ohio - MarketBeat
How Investors May Respond To NovoCure (NVCR) Securing Japanese Approval for Optune Lua in Lung Cancer - simplywall.st
NovoCure (NVCR): Assessing Valuation After Japan Approves Optune Lua for Advanced Lung Cancer Therapy - simplywall.st
Using Ichimoku Cloud for NovoCure Limited technicalsTrade Risk Assessment & Fast Moving Stock Trade Plans - newser.com
NovoCure Limited $NVCR Shares Acquired by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC - MarketBeat
Multi factor analysis applied to NovoCure LimitedDip Buying & Stepwise Trade Signal Implementation - newser.com
Rally Mode: What is the long term forecast for NovoCure Limited stock2025 Price Targets & Low Drawdown Momentum Ideas - خودرو بانک
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novocure Ltd-Aktie (NVCR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
1.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):